Scott A. Byrd
Chairman chez ACACIA PHARMA GROUP PLC
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Christine Soden | F | 66 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 9 ans |
David Ricks | M | 56 | 28 ans | |
John Brown | M | 69 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 6 ans |
Stéphane Thiroloix | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 ans |
Ed Borkowski | M | 64 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 6 ans |
Michael Bolinder | M | - | 9 ans | |
Pieter van der Meer | M | 53 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 6 ans |
Anat Ashkenazi | F | 51 | 23 ans | |
Alonzo Weems | M | - | 27 ans | |
Gabriel Fox | M | - |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 16 ans |
Jon Fyrwald | M | 63 | 19 ans | |
Daniel J. Estes | M | 43 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA.
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | 8 ans |
Travis Coy | M | 43 | 21 ans | |
Edmund Harrigan | M | 71 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 3 ans |
Edgardo Hernandez | M | - | 19 ans | |
Debra M. Hussain | F | - | 3 ans | |
Jim Bristol | M | - |
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | - |
Anne-Marie Elsley | F | - | 4 ans | |
Hugues le Bret | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 5 ans |
Chen Yu | M | - |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | - |
Claire Poulard | F | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Marvin R. Haselhorst | M | - | 10 ans | |
Thibaut Roulon | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Peter Moldt | M | 65 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | - |
James Topper | M | 62 |
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | - |
Terry Gould | M | 67 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | 8 ans |
Alessandro della Chà | M | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
William LaRue | M | 73 | 8 ans | |
Hazel Aker | F | 68 | 7 ans | |
Theodore Schroeder | M | 69 | 10 ans | |
Cam Garner | M | 75 | 10 ans | |
Kathleen A. Schaefer | F | - | - | |
Michael L. Eagle | M | 76 | 13 ans | |
Ellen Marram | F | 77 | 17 ans | |
Julian Gilbert | M | 63 | 12 ans | |
Randall L. Tobias | M | - | 12 ans | |
David Socks | M | 49 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | 5 ans |
Alan Frazier | M | 72 | 8 ans | |
Susan Mahony | M | 59 | 18 ans | |
Ronak H. Shah | M | - | 3 ans | |
Patrick Volkert Vink | M | 60 | 4 ans | |
Keith E. Brauer | M | 75 | 6 ans | |
Rolf K. Hoffmann | M | 64 | 17 ans | |
Samuel Barker | M | 81 | 8 ans | |
Michael A. Berman | M | 73 | 7 ans | |
Diana McKenzie | F | 59 | 12 ans | |
John E. Einwalter | M | 55 | - | |
Pedro Granadillo | M | 77 | 34 ans | |
Aarti Shah | M | 60 | 27 ans | |
Michael Ackermann | M | - | 2 ans | |
Gregory Davis | M | 70 | 20 ans | |
KULDEEP NEOTE | M | - | 17 ans | |
Stephen L. Newman | M | 73 | 1 ans | |
Todd W. Rich | M | 68 | 6 ans | |
Tadataka Yamada | M | 77 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | 5 ans |
Win Bischoff | M | 81 | 14 ans | |
Christopher Twomey | M | 64 | 8 ans | |
Robert A. Armitage | M | 75 | 13 ans | |
Webster Dunbar | M | 62 | 5 ans | |
Jeffrey Henderson | M | 59 | 7 ans | |
Brian Atwood | M | 71 | 8 ans | |
Melissa Barnes | F | 55 | 27 ans | |
Martin Feldstein | M | 84 | 10 ans | |
Derica Rice | M | 59 | 14 ans | |
James Cornelius | M | 81 | 12 ans | |
James Blair | M | 84 | 9 ans | |
Franklyn Prendergast | M | 79 | 22 ans | |
Kathi P. Seifert | F | 74 | 26 ans | |
Alfred G. Gilman | M | 82 | - | |
Adam Houghton | M | - | 10 ans | |
Gail H. Cassell | M | 77 | - | |
James Wooldridge | M | 58 | - | |
Lucas Montarce | M | 47 | - | |
Ann Cunningham | F | 56 | 14 ans | |
Antoine Ezell | M | 55 | 17 ans | |
Owen Wallace | M | 55 | 11 ans | |
Michael Andriole | M | 51 | 16 ans | |
Stacy Lindborg | M | 53 | 16 ans | |
Allen Melemed | M | 60 | 22 ans | |
Christopher Slapak | M | 65 | 21 ans | |
Jude Onyia | M | 60 | 26 ans | |
Robert Zerbe | M | 73 | 11 ans | |
Guido Neels | M | 75 | 12 ans | |
Ramona Sequeira | F | 58 | 12 ans | |
Gary D. Tollefson | M | 72 | 13 ans | |
Scott Canute | M | 63 | 3 ans | |
Joseph Zakrzewski | M | 60 | 16 ans | |
Zhi Sheng Chen | M | 52 | 3 ans | |
James Anderson | M | 74 | 4 ans | |
Vanessah Ng | F | - | - | |
Howard Levy | M | 70 | - | |
Timothy Garnett | - | - | 23 ans | |
T. Spencer Williamson | M | - | 3 ans | |
Ronald P. Landbloom | M | 77 | 1 ans | |
George Myles Cordell Fisher | M | 84 | - | |
Jerome H. Fleisch | M | - | 27 ans | |
Paul F. Banta | M | 63 | 8 ans | |
Scott Priebe | M | - | - | |
Steven C. Beering | M | 91 | - | |
Mark Andersen | M | 53 | 11 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 84 | 84,00% |
Royaume-Uni | 11 | 11,00% |
France | 5 | 5,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Scott A. Byrd
- Réseau Personnel